studies reinforced the working goal for any hormonal male Australia contraceptive method was to achieve uniform azoospermia to The aim of this study was to determine for the first time ensure contraception that was reliable enough by modern in humans, the efficacy of adding a low dose oestradiol to standards (Trussell and Kost, 1987; Trussell et al., 1990). a suboptimally suppressive testosterone dose in a depot
contraceptive method was to achieve uniform azoospermia to The aim of this study was to determine for the first time ensure contraception that was reliable enough by modern in humans, the efficacy of adding a low dose oestradiol to standards (Trussell and Kost, 1987; Trussell et al., 1990 ).
a suboptimally suppressive testosterone dose in a depot
These studies prompted the development of improved, secondhormonal regimen to suppress spermatogenesis in healthy generation male hormonal regimens aiming for better suppreseugonadal men. Twenty-six healthy men were randomized sion (i.e. universal azoospermia, elimination of semen moninto groups that were treated by a single subdermal itoring) and enhanced delivery to optimize compliance through implantation of either 600 mg testosterone alone (T; n ⍧ improved depot hormonal formulations which allow longer 11) or together with 10 mg (TE10, n ⍧ 7) or 20 mg (TE20, and more convenient freedom between dosages. n ⍧ 8) oestradiol. Administration of oestradiol produced
Various hormonal regimens have shown promise for such a dose-dependent increase in peak plasma oestradiol at 1 development of practical hormonal male contraceptive month and prolonged suppression of plasma LH and FSH approaches (Handelsman, 1999) . The simplest and most widely leading to significantly enhanced suppression of sperm used approach has been to use androgen-alone regimens. In output. Despite the augmented spermatogenic suppression, addition to the WHO studies using weekly testosterone and there was no significant difference in the proportions oestradiol (WHO Task Force on Methods for the Regulation achieving azoospermia (6/26, 23%) or severe oligozooof Male Fertility, 1990 Fertility, , 1996 , depot forms of testosterone spermia (<1 or <3⍥10 6 spermatozoa per ml, 7/26, 27%) such as subdermal testosterone implants (Handelsman et al. , and overall these proportions were inadequate to provide 1992) or injectable testosterone buciclate (Behre et al., 1995) reliable contraception according to the standards identified or undecanoate (G.Y.Zhang, personal communcation) have in World Health Organization male contraceptive efficacy shown various degrees of spermatogenic suppression, although studies. Total and free testosterone remained within the none attains the goal of producing uniform azoospermia. The eugonadal reference range for young men throughout the genetic and/or environmental reasons for this non-uniformity study. While the lower oestradiol dosage had minimal of spermatogenic suppression remain to be elucidated (Handspermatogenic suppression effects, the higher dose pro elsman et al., 1995) . In order to enhance the spermatogenic duced dose-limiting adverse effects of androgen deficiency suppression, combination regimens have been developed. and/or oestrogen excess between the fourth and sixth month of the study. This appeared to be due to the unexpectedly These use a second, gonadotrophin-suppressing agent coupled prolonged, low concentration of oestradiol release from with androgen replacement to replace endogenous androgen the oestradiol implants. There were no significant secretion which is inevitably abolished. Despite sacrificing treatment-related changes in body composition, lipids, prosimplicity, combination regimens might enhance spermatogenic state-specific antigen, haematological or biochemical varisuppression while reducing mutually the minimally effective ables. Thus oestradiol has a low therapeutic window and doses of both active agents. Effective regimens featuring dose-limiting side-effects at dosages that fail to achieve second agents so far include gonadotrophin-releasing hormone the uniform azoospermia required of an effective male (GnRH) antagonists (Cummings and Bremner, 1994) or synhormonal contraceptive regimen.
thetic progestins (Patanelli, 1977; Schearer et al., 1978;  HandKey words: family planning/male contraception/oestradiol/ elsman, 1999). The GnRH antagonists are, however, expensive, spermatogenesis/testosterone difficult to formulate, may cause irritation due to histamine release and require large daily doses. Synthetic progestins are available mostly in oral formulations, which entails routedependent, first-pass hepatic overdosage, and regimens involIntroduction ving concurrent oral and injectable dosing are inherently impractical. Another category of sex steroid not evaluated as A hormonal male contraceptive must suppress reversibly sperm output to amounts that reliably prevent conception with a second agent for hormonal male contraception is that of the 10 mg oestradiol arm was closed and a third arm using a higher oestrogens. Pioneering studies by Ewing and associates in the oestradiol dose (20 mg) was opened. In order to retain balance 1970s demonstrated that the addition of a low dose of oestradiol between remaining open arms of the study, further randomization to to testosterone greatly enhanced suppression of spermatogenthe testosterone alone and testosterone plus 20 mg oestradiol arms esis in a wide variety of animals including non-human primates was undertaken using urn randomization (Wei and Lachin, 1988) . In but this concept was never tested in man. The present study this procedure, known as unbalanced randomization, the probability was designed to test Ewing's conjecture, that the addition of of assignment to either group was variable, according to the current a small dose of oestradiol to a depot testosterone formulation state of imbalance in randomization, rather than fixed. At the time of is required for maximal suppression of mammalian spermatorandomization of each subject, P (the probability of assignment genesis in humans.
to the smaller group) was recalculated from its definition as 2 d /(2 d ϩ 1) where d was the difference in numbers in each groups which it was intended to balance. The subject was then randomized
Materials and methods
according to the drawing of a random P value from a uniform [0,1] distribution. Participants Volunteers were recruited from the general population by advertising Procedures in print and broadcast media. Recruitment was aimed at men aged 18-All participants underwent a single implantation procedure under 45 years, in good general health with normal clinical and biochemical local anaesthesia at entry to the study. At that implantation procedure baseline evaluation (including routine tests of liver, kidney and all volunteers received according to their randomization, testosterone haematological function), normal reproductive function (including 600 mg (three 200 mg implants) alone or together with an oestradiol two semen analyses and blood hormone levels). They were required implant [10 mg or 20 mg implant; supplied by Organon (Australia) to provide written informed consent agreeing to comply with protocol Pty Ltd, Sydney, Australia]. Testosterone and oestradiol were adminisand were cautioned about competing in elite sports requiring urinary tered as implants of fused cylindrical rods (testosterone 12 mm long, drug screening. Men were excluded if they had known cardiovascular, 4.5 mm diameter; oestradiol 2.5 mm long, 2.25 mm diameter) of prostate, reproductive, major psychiatric or other serious medical pure crystalline steroid without excipients. Subdermal implantation disorders, a history of drug abuse, were taking any regular medication was performed by skilled operators on the lateral anterior abdominal or had contraindications to minor local surgery or administration of wall under local anaesthetic. No sutures or antibiotics were required testosterone or oestradiol. In addition, men entering the study after and the biodegradable implants did not require removal. the interim review which allowed a higher oestradiol dose were During baseline evaluation, participants provided two sets of blood screened for the factor V Leiden mutation, a naturally occurring and semen samples and during the 12 months of the study the mutation causing high risk of venous thromboembolism in young participants provided monthly blood and semen samples for 12 women taking oral oestrogens (Vandenbroucke et al., 1994) . The months and underwent body composition (bioelectrical impedence) study was approved by the Central Sydney Area Health Service measurement at months 1-3, 6 and 12. Ethics Review Committee (RPAH zone) and was conducted within National Health and Medical Research Council (NHMRC) guidelines Assays for human experimentation.
Semen samples collected by masturbation after at least 2 days without Design ejaculation were analysed by standard WHO methods (WHO, 1992) . Plasma samples were stored for measurement in commercial The study had a randomized, open-label, parallel group design immunoassays for LH (Abbot Axysm, Abbott Laboratories, Abbott conducted in a single centre. The primary efficacy end-point was the Park, IL, USA), FSH (Abbot Axysm), total testosterone (Biomedic degree of suppression of sperm output as indicated by the proportion Immunlyte, Diagnostic Products Corp., Los Angeles, CA, USA), achieving azoospermia and the time-course of sperm concentrations.
oestradiol (Delfia, Wallac Oy, Turku, Finland), SHBG (Biomedic The secondary efficacy end-points were the time course of plasma Immulyte) and PSA (Delfia). Between-assay coefficients of variation reproductive hormones (total and free testosterone, oestradiol, LH, were Ͻ10% for all assays. Free testosterone was measured by an in-FSH). The safety end-points were spontaneously reported adverse house centrifugal ultrafiltration method (Handelsman et al., 1990 , effects, standard physical examination, time course of metabolic 1996) with a between-assay coefficient of variation of 12%. Clinical indicators of androgen effects [sex hormone binding globulin (SHBG), chemistry assays (liver function, renal function and lipids) were lipids], prostate-specific antigen (PSA), body composition (weight, undertaken by routine autoanalyser methods (Handelsman et al., bioimpedance analysis), clinical chemistry (renal, hepatic and haema-1990, 1996) . tological function) and acceptability (psychometric measures of mood, Changes in body composition were determined after an overnight behaviour and acceptability). Gynaecomastia was defined as glandular fast by measurement of body weight to the nearest 0.1 kg and the enlargement of breast tissue reported spontaneously by participants percentage fat was determined by bioelectrical impedence analysis and/or noted at routine physical examination by study personnel.
using the SEAC Model BIM 3.0 bioimpedence meter implementing Eligible volunteers were randomized into groups receiving either the Lukaski algorithm (Lukaski, 1987) . Using body weight and testosterone alone or testosterone plus oestradiol implants as a single percentage fat, fat mass and lean body mass were calculated. The dose at the start of the study. The testosterone dose was 600 mg reproducibility of the bioimpedence measurements was 5.6% for lean (three 200 mg implants) for all groups. Initially, the oestradiol dosage mass and 7.7% for fat mass (pooled within -subject coefficient of was 10 mg, which was achieved by bisecting a 20 mg oestradiol variability for 9 people measured on 3 occasions at 3 month intervals). implant under sterile conditions immediately prior to implantation. Due to the uncertainty in estimating an appropriate oestradiol dosage Data analysis for healthy young men for whom no published data were available, an interim summary of efficacy blinded to group assignment was Continuous variables were analysed by analysis of variance for factorial or repeated measures designs with post-hoc testing by undertaken when half the participants were recruited. As this indicated negligible difference between groups in spermatogenic suppression, Duncan's test or by Student's t-test as appropriate using SAS (SAS 1 (9) 3 (43) 3 (38) 0.241 (Ͻ1 ϫ 10 6 /ml) T ϭ 600 mg testosterone group; TE10 ϭ 600 mg testosterone ϩ 10 mg oestradiol group; TE20 ϭ 600 mg testosterone ϩ 20 mg oestradiol group; BSA ϭ body surface area; BMI ϭ body mass index; SGBH ϭ sex hormone binding globulin.
Institute, Cary, NC, USA) version 6.12 software. Oestradiol treatment due to job transfers away from Sydney) who discontinued effects were considered present when either there were differences prematurely all completed at least 6 months in the study.
between main effects of treatment groups or when there was a significant treatmentϫtime interaction indicating significantly differSperm output ent time-courses for treatment groups. Dose-dependent effects of By chance, baseline sperm concentration was higher in the oestradiol were tested by suitable linear contrasts. Non-gaussian TE20 group (Table I) . The nadir sperm concentration differed sperm output data was cube-root transformed prior to analysis. Categorical variables were analysed by exact contigency table methods significantly between groups but these could not be solely due ment P ϭ 0.004) in a dose-dependent manner for the first 6 months as illustrated by the different time course (treatmentϫtime interaction, P Ͻ 0.0001) of sperm concentraResults tions (Figure 1 ).
Participants
The overall proportion of men achieving azoospermia was 6/26 (23%) and severe oligozoospermia (Ͻ1 or Ͻ3ϫ10 6 Thirty-five volunteers were screened to find 26 eligible men spermatozoa per ml) was 7/26 (27%) but did not differ who completed screening and were randomized to enter the significantly between the three groups. Oestradiol (pooling study. One man was excluded on the basis of factor V Leiden both dose groups) appeared to enhance the likelihood of mutation. Ultimately, 11 men entered the testosterone alone achieving azoospermia [33 versus 9%, odds ratio (OR) 5.0, group (T), seven the testosterone plus oestradiol 10 mg (TE10) one-sided 95% confidence interval (CI) 0.5-128] or severe and eight the testosterone plus oestradiol 20 mg (TE20) arms.
oligozoospermia (40 versus 9%, OR 6.7 95%, CI 0.8-166), The participants were well matched in age, height, body although neither confidence interval excluded 1.0 with their weight, lean body weight, fat mass, testis and body size and width indicating the relatively low power of the study to baseline hormones (Table I ). The reliability of follow-up was exclude a difference in proportions (for one-sided α ϭ 0.05, high with only nine isolated missed visits (2.5% of scheduled visits) and the five men (three for personal reasons, two azoospermia 29%, oligozoospermia 45%). Treatment groups differed significantly in semen volume and sperm motility (P Ͻ 0.01) but without any evidence of a dose-dependent effect of oestradiol. Neither abstinence time the first monthly blood sampling (Figure 2) . At 1 month, plasma oestradiol peaked at 192 Ϯ 23 pmol/l for TE20, groups with the time course of the T and TE10 groups being similar whereas the TE20 group had markedly greater and 149 Ϯ 6 pmol/l for TE10 and 96 Ϯ 7 pmol/l for T groups. These represented an increase of 92 Ϯ 24 pmol/l (97 Ϯ 27%), prolonged suppression (Figure 3 ). Plasma SHBG concentrations were unchanged over time or between treatment groups 50 Ϯ 6 pmol/l (53 Ϯ 9%) and 4 Ϯ 4 pmol/l (5 Ϯ 4%) respectively over their own pretreatment baselines. Sub- (Figure 3) . sequently, by the fourth month, there was no longer any Safety significant difference in oestradiol concentrations between oestradiol treated groups; however, both oestradiol treated No unexpected or major adverse clinical effects were reported nor any biochemical abnormalities (including liver function groups demonstrated an unexpectedly prolonged, continuous low-grade oestradiol release until the end of the study. In tests) observed. There were few spontaneous reports of minor adverse effects in the T (pellet site pain, one; libido increased, contrast, the men who did not undergo oestradiol implantation had stable plasma oestradiol levels throughout the study.
one; libido decreased, one; snoring, one) or TE10 (pellet extrusion, one; pellet site pain, one; nipple tenderness, one) Testosterone concentrations were stable within the middle of the eugonadal reference range throughout the study for the groups compared with the TE20 group (15). In the TE20 group most (11/15) complaints were attributable to symptoms of T and TE10 groups whereas the TE20 group demonstrated a transient decrease in total and free testosterone concentrations androgen deficiency Ϯ oestrogenic effects (lethargy and/or tiredness, four; nipple tenderness, two; gynaecomastia, two; between months 2 and 6 (Figure 2 ). Subsequently after the first 6 months, plasma total and free testosterone concentrations libido decreased, three) usually between the fourth and sixth month after entry. The other reports of minor adverse effects did not differ between groups or over time.
Plasma LH concentrations were reduced in all treatment in the TE20 group included single reports of pellet extrusion, pellet site pain, increased energy and acne. Twelve men groups with the time-course of the T and TE10 groups being virtually identical, whereas the TE20 group had greater and reported no side-effects and three men reported more than one side-effect. Gynaecomastia, reported spontaneously and more sustained suppression particularly between months 2-6 (Figure 3) . Plasma LH was maximally reduced in the T and confirmed by palpation, was present in two men in the higher oestradiol dose group. None of the other participants either TE10 groups at 1 month whereas nadir LH levels were sustained between months 1 and 3 in the TE20 group.
reported or had palpable evidence of gynaecomastia. There were no significant changes in total, high density Plasma FSH also showed marked suppression in all three implants, doses of testosterone and oestradiol approximating the endogenous production rates when combined provided highly effective and reversible suppression of spermatogenesis and fertility (Ewing et al., 1983a; Lobl et al., 1983) with no adverse effects on somatic tissues of rhesus monkeys (Ewing et al., 1983b) . Similar results were also obtained in rats and rabbits Ewing et al., 1973 Ewing et al., , 1977 Ewing et al., , 1979 Berndtson et al., 1975) but this concept had never been tested in humans. Despite confirming that oestradiol augments testosterone-induced suppression of human spermatogenesis, the present study also shows a relatively narrow therapeutic margin and, even at maximally tolerated doses of parenteral oestradiol, the suppression of spermatogenesis is still inadequate by the standards required to provide reliable contraception by modern standards (WHO Task Force on Methods for the Regulation of Male Fertility, 1990 Fertility, , 1996 . Hence it is unlikely that a depot testosterone-oestradiol combination could form the basis of a practical depot hormonal contraceptive regimen for men.
The present study extends our previous findings using depot steroid implants (Handelsman et al., 1990 (Handelsman et al., , 1992 in which it was shown that over the full range of testosterone daily release rates covering the normal daily production rates the highest dose of testosterone alone (six 200 mg; 7.8 mg/day testosterone release rate) produced equally effective spermatogenic suppression to that of testoster- (Figure 4) testosterone have been confirmed by other groups (Bebb or in haematological variables (haemoglobin, haematocrit, et al., 1996; Meriggiola et al., 1996 Meriggiola et al., , 1997 Meriggiola et al., , 1998 Wu, 1999) . leukocyte or platelet counts; data not shown) between treatment Nevertheless, regimens combining an oral and injectable medgroups. There was a small but significant decline in haemoication for male contraception are inherently impractical. A globin and haematocrit levels equally in all groups over time.
major advantage of a combination depot hormonal approach is There were no significant changes in body weight, lean body not only greater convenience but also avoiding the undesirable mass, fat mass or percentage fat as measured by bioimpedance metabolic effects inherent in an oral medication due to its analysis according to treatment group or over time (data inevitable first-pass hepatic overdosage. not shown).
The effectiveness of oestradiol in augmenting spermatogenic suppression is illustrated by the dose-dependent enhancement Discussion in the decreasing sperm output although the modest magnitude of the oestradiol effect is such that the increased proportions The present study demonstrates that oestradiol significantly but modestly enhances testosterone-induced suppression of achieving azoospermia were not statistically significant in this study. This discrepancy was due to the loss of statistical power spermatogenesis in humans, vindicating Ewing's prediction from extensive animal experiments  when comparing analysis of sperm output as a continuous variable over time compared with as a dichotomized categorical Ewing et al., 1973 Ewing et al., , 1977 Ewing et al., , 1979 Ewing et al., , 1983a Berndtson et al., 1975; Lobl et al., 1983) . Pioneering studies by Ewing and variable. The dose-dependent increases in plasma oestradiol were also associated with dose-dependent decreases in plasma associates over the decade from 1974 to 1983 demonstrated that the addition of a low dose of oestradiol to testosterone LH and FSH indicating that the enhanced suppression of spermatogenesis was due to more complete inhibition of provided optimal suppression of spermatogenesis, superior to that of testosterone alone where sex steroids were administered pituitary gonadotrophin secretion via steroidal negative feedback. It is difficult to explain the apparent discrepancy between via a true parenteral steroid depot (Ewing et al., 1983a; Lobl et al., 1983) . In their studies using non-biodegradable silastic extent of gonadotrophic and spermatogenic suppression accord- ing to oestradiol dose. Adjusting for baseline sperm concentraapplication in male contraception (Sundaram et al., 1993) , is metabolized to a potent synthetic oestrogen, 7α-methyl tion (by examining decrement) showed no effect of baseline sperm concentrations on gonadotrophin and spermatogenic oestradiol (LaMorte et al., 1994 (LaMorte et al., , 1995 . The present study predicts that this active metabolite may enhance spermatogenic suppression; this does not prove, however, that baseline differences were irrelevant. In none of the arms were gonadotrophins suppression but the degree to which it may produce other oestrogenic effects will influence its overall acceptability. fully suppressed which highlights the need for complete gonadotrophin suppression as a necessary, but not sufficient,
The occurrence of androgen deficiency/oestrogen excess symptoms in the higher oestradiol dosage group appears to be condition for producing the complete inhibition of sperm output required for reliable male contraception. Although these due to both the unexpectedly prolonged duration of action of the oestradiol implants that exceeded the duration of action of effects of oestradiol appear to be manifest via central inhibition of gonadotrophin secretion, it is, however, impossible to fully the relatively low testosterone implant dosage. The testosterone dose in this study (600 mg) is lower than is currently used for rule out additional direct effects of oestradiol on testicular function. The limitations of oestradiol illustrated in the present androgen replacement therapy (800 mg) in naturally occurring androgen deficiency states . Nevertheless study were that while the lower dose had negligible effects, only a two-fold higher dose produced dose-limiting adverse our previous pharmacokinetic studies indicated clearly that the 600 mg testosterone dose should be sufficient for 4 months effects. Hence oestradiol has a narrow therapeutic window and, even at higher doses that would not be clinically acceptable, the (Handelsman et al., 1990) . The unexpectedly prolonged low concentrations of oestradiol released from 20 mg implants proportions achieving azoospermia, however, was far from sufficient. It is unclear whether the pattern of oestradiol effects lasted many months longer than the expected 2-3 month duration of action in women. Such low levels of oestradiol would also apply to the newer mixed partial synthetic oestrogen agonists such as tibolone and raloxifene which interact with release would not have been detectable either clinically or biochemically in women but apparently still exert biologically the same oestrogen receptors.
An additional implication arising from the present study for significant effects in healthy eugonadal men. The side-effects consistent with oestrogen excess and/or androgen deficiency the further development of male hormonal contraception is that, for novel synthetic androgens, aromatizability is a desirable were reported between 4 and 6 months after hormone administration. This suggests that, despite plasma testosterone concenproperty for efficacy although its risk:benefit ratio for safety and acceptability would depend on the quantitative importance trations still within the eugonadal reference range, there was a state of partial androgen deficiency due to unopposed and potency of any oestrogenic metabolites arising. For example, the synthetic nandrolone derivative, 7α-methyl, oestradiol release continuing to inhibit endogenous androgen secretion. The fact that higher oestradiol levels (250-19-nortestosterone (MENT), being developed for possible 300 pmol/l) sustained for up to 18 months without such sidefor known as well as unknown covariables at entry into a study, cannot always ensure balance. The use of unbalanced effects in the WHO studies using weekly i.m. injections of 200 mg testosterone enanthate (Handelsman, personal com-('urn') randomization in this study did allow optimal efficiency in distribution of subjects and final study arm size. The munication) suggests that the side-effects observed in this study might have been overcome or prevented if exogenous observation that men entering the study later had significantly higher sperm concentrations than those entering early is testosterone had been maintained for longer such as with a higher starting dose (Handelsman et al., 1990) .
reminiscent of an earlier observation that recruitment of selfselected volunteers for research studies on sperm output can In men a safety concern regarding oestradiol supplementation that did not materialize was the hypothetical risk of arterial produce major and unpredictable bias (Handelsman, 1997) . In this instance, a similar bias was observed even within the thromboembolism. This apprehension originates from the VA-CURG (Veterans Administration Cooperative Urological framework of a single study extending the previous observation of such bias between studies within a single centre and the Research Group) studies in the 1960s (VACURG, 1967) and the Coronary Drug Project in the 1970s (Coronary Drug Project same investigators. The particular susceptibility, of studies requiring semen samples, to participation bias further emphasResearch Group, 1970; Anonymous, 1973) in which older men being treated with high dose oral oestrogen manifested excess izes the invalidity of extrapolations of semen findings from uncontrolled, convenience samples of unrepresentative selfdeaths due to arterial thromboses. Recent studies show that parenteral administration of high dose oestradiol, resulting in selected volunteers (Carlsen et al., 1992) . Recruitment to studies requiring semen samples is difficult and various recruit-10-fold higher circulating oestradiol concentrations than in the present study, has minimal adverse effects on safety (including ment strategies are utilized. Seasonality seems an unlikely explanation in our study, as recruitment for all arms overlapped vascular thrombosis) in older men with prostate cancer (Carlstrom et al., 1997; Henriksson et al., 1999) . These findings seasons. Seasonal effects on human sperm output are, at best, inconsistent and smaller in magnitude than that observed suggest the absence of arterial thrombosis in this study may reflect predominantly the non-oral route of oestrogen adminisbetween groups in this study. The conclusion from this study that a testosterone-oestradiol tration rather than the lower oestrogen dosage and the younger age of participants in the present study. The safety experience hormonal combination cannot form the basis of a useful depot regimen for male contraception. Nevertheless aromatization of in this study was also in keeping with the observation that higher oestradiol concentrations (250-300 pmol/l) had been a potent synthetic androgen is a positive feature for efficacy but may have ambiguous value for safety and acceptability. sustained for up to 18 months in men receiving weekly i.m. injections of 200 mg testosterone enanthate (WHO Task Force This study again highlights the advantages of depot hormonal approaches for hormonal contraception for men and further on Methods for the Regulation of Male Fertility, 1990 Fertility, , 1996 without significant evidence of thromboembolic events (Wu studies of improved depot formulations would be of great interest. et al., 1996) .
The present study again illustrates the advantages of depot hormonal regimens. In addition to the major user-friendly
